Index

A
Accelerated hyperfractionated radiation, 81–82
Affymetrix U133A microarrays, 45–46
American Cancer Society (ACS), 22, 23
American Joint Committee on Cancer tumor node metastasis (AJCC TNM), 51, 52
Amphiregulin (AREG), 113–114
Angiogenesis
discovery, 34–35
factors influencing, 35
FES proto-oncogene, 36
osteoprotegerin, 36
VEGF, 35–36
Anthracycline-and taxane-resistant recurrent breast cancer, 135–136
Antiangiogenic therapy, 123–124
Antineoplastic agents
efficacy assays, 102–104
forms of usage, 102
lapatinib, 104
mechanisms of action and response rate, 102, 103
selection criteria, 102
Autologous stem cell transplantation (ASCT), 75

B
Bacille Calmette-Guérin (BCG), 74
BCRP. See Breast cancer-resistant protein (BCRP)
Bevacizumab, 11
Biphosphonates, 136–137
BI-RADS. See Breast imaging reporting and data system (BI-RADS)
Brachial plexopathy, 89–90
Brain metastases (BM), 100–101
Breast abscess, 53
Breast cancer
diagnosis, 21
early detection
advantages, 22
breast self-examination, 22
limiting factors, 23–24
mammography, 22–23
published assays, 23
USPSTF, 23
IBC, 24–25

C
cDNA microarrays, 44–45
Chalkley method, 37
Chemotherapy (CT)
antecedents, 73
anthracyclines, 74–75
HDCT, 75–76
recurrent breast cancer
first-line systemic treatment, 134
HER2-positive patient, 134–135
patient classification, 133
treatment recommendations, 134
triple-negative patient, 135
surgery, 73
taxanes, 75, 76
uses, 73–74
Concurrent radiotherapy, 81
Cyclooxygenase-2 (COX-2), 41, 115

D
Dermal lymphatic invasion (DLI), 3
Disease-free survival (DFS), 73
Dose escalation, 80

incidence and mortality rates, 16–17
national panorama, 18–19
prevention, 24
prognostic factors, 21–22
risk factors
alcohol and obesity, 20
external hormone use, 20
fetal exposure, 19
genetic, 19
physical activity and diet, 20
prevalence and distribution, 19, 20
reproductive, 19–20
unhealthy lifestyle, 20–21
study purpose, 15
worldwide incidence, 16
Breast cancer-resistant protein (BCRP), 101
Breast imaging reporting and data system (BI-RADS), 21
Breast reconstruction, 58
E
Eastern Cooperative Oncology Group (ECOG), 124
E-cadherin
epithelial cells adhesion, 37
expression of, 38
MARY-X spheroids, 38–39
MUC1, 39–40
patchy-cytoplasmic MUC1 expression, 39
SUM149 cells, 39
tumor cell emboli formation, 38
Epidermal growth factor receptors (ErbB), 112
Epithelial growth factor receptor (EGFR), 110
Epithelial-mesenchymal transition (EMT)
CD44+/CD24, 43
cell division, 41, 43
characteristics, 44
NOTCH1, 44
SUM149, 44
TDLU, 43
in vitro propagation system, 43
Estrogen receptor (ER), 32
Extended field-of-view (EFOV), 65
Extracellular regulatory kinases (ERK), 111
F
Fluorescent in situ hybridization (FISH), 134
18-Fluorodeoxyglucose (18FDG), 69
5-Fluorouracil (5-FU), 73
5-Fluorouracil, adriamycin, cyclophosphamide (FAC), 10, 11, 74, 75
G
German Preoperative Adriamycin Docetaxel Group (GeparTrio) trial, 75, 96
H
HER2/neu overexpression, 32–34
High-dose chemotherapy (HDCT), 75–76
Hormonal receptors, 32, 33
Hormone therapy, 133
Human epithelial growth factor receptor-2 (HER2), 110, 114
I
IBC. See Inflammatory breast cancer (IBC)
IC. See Inflammatory carcinoma (IC) imaging
Idiopathic granulomatous mastitis (IGM), 54
Infectious mastitis, 53
Inflammaging, 110–111
Inflammatory breast cancer (IBC) See also Recurrent inflammatory breast carcinoma
abscess, 2, 3
authors involved, 5, 8
bevacizumab, 11
breast reconstruction, 58
characterization, 51
clinical presentation, 1, 2, 52
clinical signs and symptoms, 52–53
CXCR4 expression, 3–4
definition, 51–52
diagnosis and staging evaluation, 55–56
diagnostic criteria, 2
differential diagnosis
infectious mastitis and breast abscess, 53
lymphoma or leukemia, 54–55
noninfectious mastitis, 53–54
radiation dermatitis, 54
DLI, 3
E-cadherin expression, 3
FAC, 10, 11
follow-up, 58 (see also Recurrent breast cancer)
HER2 expression, 4
invasive ductal carcinoma, 2
lapatinib and paclitaxel, 12
mastitis, 2
molecular biology (see Molecular biology, IBC)
NF-κB activation and ILGF signaling, 4
pathology (see Pathology, IBC)
p53 expression, 3
prevalence, 1–2
primary chemotherapy, 4–5
PTEN, 3
publications, 5–7, 9, 10
radiation therapy, 5
sentinel lymph node biopsy, 58
surgical treatment
advantages, 57
locoregional treatment, 57
mastectomy, 57
selection criteria, 58
taxanes and trastuzumab, 5
treatment, 56–57
Inflammatory breast carcinoma (IBC). See Inflammatory breast cancer (IBC)
Inflammatory carcinoma (IC) imaging
clinical diagnosis, 61
importance, 62
incidence, 61
magnetic resonance
enhancement curve types, 66–68
procedure, 66
skin thickening, 66, 68
STIR sequence, 68–70
washout phenomenon, 68
mammography
digital vs. conventional, 62, 65
inflammatory changes, 62, 63
mammary parenchyma density, 62
mammographic patterns, 62, 64
skin thickening, 62
nuclear medicine findings (see Nuclear medicine)
symptoms, 61–62
ultrasound mammography
advantages, 65
EFOV, 65
regional lymphadenopathies, 66, 67
skin thickening, 66
Index

Insulin-like growth factor (ILGF), 4
Interleukin 6 (IL-6), 110
Interleukin 10 (IL-10), 110
International Agency for Research on Cancer (IARC), 16, 17
Invasive ductal carcinoma, 2

L
Lactation, 111
Lapatinib, 104, 121–122
Locally advanced breast cancer (LABC), 51, 56
Local recurrence, 131–132
Locoregional recurrent disease, 99–100
Locoregional treatment, 56–57
Lung resistance-related protein (LRP), 101
Lymphedema, 89
Lymphoma, 54–55

M
Magnetic resonance (MR)
  enhancement curve types, 66–68
  procedure, 66
  skin thickening, 66, 68
  STIR sequence, 68–70
  washout phenomenon, 68
Mammography, 22–23, 56
  digital vs. conventional, 62, 65
  inflammatory changes, 62, 63
  mammary parenchyma density, 62
  mammographic patterns, 62, 64
  skin thickening, 62
Mammospheres, 43
Mastectomy, 57
Mastitis, 2
Matrix metaloproteinases (MMP), 113
Mesenchymal-epithelial transition (MET), 110
Metabolic syndrome (Me Sy), 110–111
Metformin, 111–112
Methotrexate and vinblastine (MV), 74
Molecular biology, IBC
  definition and classification, 109
  genomic balance, 112
  molecular factors
    ERK and MAPK inhibitors, 111
    IGF, 111
    inflammaging, 110–111
    lactation, 111
    Me Sy, 111
    metformin-type antidiabetic agents, 111–112
    obesity, 110
    WISP3/CCN6, 111
  molecular subtypes, 114
  new therapeutics, 115
  prognostic markers
    amphiregulin, 113–114
    caveolin-1, 112
    E-cadherin, 112–113
    ErbB, 112
    matrix metaloproteinases, 113
    MET process, 113
    pro-inflammatory cytokines and chemokines, 109–110
    Rho C GTPase oncogene, 114
    MR, See Magnetic resonance (MR)
    mTOR inhibitors, 123
    Multi-isocenter technique, 85
    Multimodal therapy, 94
    Multiple-drug-resistant protein type 1 (MDR1), 101

N
National Cancer Institute (NCI), 124
National Institute of Cancer in Mexico (INCan), 71–72
Neoadjuvant chemotherapy, 57, 58
Neoadjuvant Herceptin (NOAH) study, 95–96
Neratinib, 122
Noninfectious mastitis, 53–54
Nonsteroidal anti-inflammatory drugs (NSAID), 115
Nuclear factor-kappa beta (NF-κB), 4, 110
Nuclear medicine
  INCan study, 71–72
  PEM, 71
  PET-CT
    18FDG-marked radiotracer, 69
    limitation, 69, 71
    uses, 69

O
Obesity, 110
Osteoprotegerin (OPG), 36

P
Pathology, IBC
  adhesion molecules (see E-cadherin)
  angiogenesis (see Angiogenesis)
  biopsy, 30
  characteristics, 29
  conventional biomarkers
    ERBB family, 32–34
    hormonal receptors, 32, 33
    proliferation markers, 34, 35
  COX2 overexpression, 41
  differential diagnosis, 32
  discovery, 29
  gene expression profiling
    Affymetrix U133A microarrays, 45–46
    cDNA microarrays, 44–45
    miRNA expression, 46
    RT-PCR, 45
  histological findings, 30–31
  macroscopic pathology, 30
  molecular markers, 41, 42
  NF-κB activation, 41
  objectives, 29–30
  p53 gene mutation, 40–41
  p27^{kip1}, 4
Pathology, IBC (cont.)
RHOC GTPase and WISP3, 40
stem cells/EMT (see Epithelial-mesenchymal transition (EMT))
tumor vascularity assessment, 36–37
vessel formation, 37
Pazopanib, 124
Pertuzumab, 122
PET-CT. See Positron emission tomography-computed tomography (PET-CT)
P-glycoprotein, 101
Phosphatase and tensin (PTEN) homolog, 3
Positron emission mammography (PEM), 71
Positron emission tomography-computed tomography
(PET-CT), 82–83
18FDG-marked radiotracer, 69
limitation, 69, 71
uses, 69
Postoperative radiotherapy, 80–81
Poussee evolutive (PEV) breast cancer, 51
Preoperative radiotherapy, 80
Progesterone receptor (PR), 32
Proliferation markers, 34, 35

R
Radiation dermatitis, 54
Radiation pneumonitis, 89
Radiotherapy (RT)
accelerated hyperfractionated radiation, 81–82
bolus use, 86–87
brachial plexopathy, 89–90
characterization, 79
concurrent, 81
conventional simulation technique
CT-based treatment planning, 84
field design and, 83, 84
planning CT data acquisition, 83–84
radiopaque mark, 83
setup and field arrangement, 83
dose escalation effects, 80
initial staging studies, 82–83
lymphedema, 89
neoadjuvant CT and mastectomy, 79–80
postoperative, 80–81
preoperative, 80
radiation pneumonitis, 89
vs. surgery, 80
survival rates, 79
technique
five-field, 84, 85
multi-isocenter technique, 85
oblique electron field, 84
three-electron fields, 84–85 (see also Three-field technique)
toxicity
acute, 87–88
cardiac, 88–89
Real-time polymerase chain reaction (RT-PCR), 45
Recurrent breast cancer
adequate follow-up recommendations, 130
anthracycline-and taxane-resistant, 135–136
biphosphonates role in prevention, 136–137
definition, 129–130
global survival rates, 129
hormone receptors and HER2 expression, 130
local or disseminated disease classification, 131
local recurrence, 131–132
restaging, 130–131
therapeutic strategy selection, 131
treatment
chemotherapy and target therapies
(see Chemotherapy (CT))
complications, 137
duration, 137
elderly patients, 136
hormone therapy, 133
risk and, 132–133
scope establishment, 131
Recurrent inflammatory breast carcinoma
antineoplastic agents
efficacy assays, 102–104
forms of usage, 102
lapatinib, 104
mechanisms of action and response rate, 102, 103
selection criteria, 102
BM management, 100–101
IBM
AJCC-TNM criteria, 94
clinical-stage frequency, 94
incidence, 93
primary chemotherapy efficacy, 95–96
standard treatment, 94–95
survival rates, 94
inflammatory carcinoma, 93
locoregional recurrence, 99–100
molecular biology, 104–105
prevalence, 96–97
prognostic factors, 98–99
recurrence sites and time of presentation, 97–98
systemic recurrence treatment, 101–102
Response Evaluation Criteria in Solid Tumors (RECIST), 104
Restaging, 130–131
RHOC GTPase, 40
Rho C GTPase oncogene, 114
RT. See Radiotherapy (RT)

S
Sentinel lymph node biopsy, 58
Short T1 inversion recovery (STIR) sequence, 68–70
SU5416, 124
Surveillance, Epidemiology, and End Results (SEER), 1
SWOG0012 study, 96
T
Tamoxifen, 133
Target therapy
antiangiogenic therapy, 123–124
benefits, 120
chemotherapy, 119
E-cadherin, 119
HER2 and, 120–121
lapatinib, 121–122
mTOR inhibitors, 123
neratinib, 122
nuclear factor-kappa beta, 120
pertuzumab, 122
p27kip1 dysregulation, 120
TKI of the VEGF receptor, 124–125
trastuzumab, 121
trastuzumab-DM1, 122–123
WISP3 expression, 120
Taxanes, 75
Taxotere, adriamycin and cytoxan (TAC), 75
Temsirolimus, 123
Terminal ductal lobular units (TDLU), 43
Three-field technique
3D planning, 86, 87
intensity-modulated radiotherapy, 86
rod-and-chain method, 86
standard technique, 84, 85
supraclavicular fossa and axillary treatment, 86, 87
Trastuzumab, 121
Trastuzumab-DM1 (T-DM1), 122–123
Tuberculous mastitis, 53
Tumor suppressor gene p53 (TP53), 40
U
Ultrasonography, 56
Ultrasound (US) mammography
advantages, 65
EFOV, 65
regional lymphadenopathies, 66, 67
skin thickening, 66
US Preventive Services Task Force (USPSTF), 23
V
Vascular endothelial growth factor (VEGF), 34–36, 123
Vasculogenic mimicry, 37
Visceral adiposity, 110–111
W
WISP3, 40
World Health Organization (WHO), 17